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Persistent Patent ductus arteriosus (PDA) is a common finding in extremely low
gestational age newborn infants and its prevalence is inversely proportional to the
gestational age. The presence of a persistent PDA is associated with increased mortality
and several significant morbidities including intraventricular hemorrhage, pulmonary
hemorrhage, necrotizing enterocolitis, and chronic lung disease or bronchopulmonary
dysplasia. However, treating PDA has not been demonstrated to have beneficial impact
on the long term outcomes. Currently there is no consensus on whether to treat the
PDA or not, and if treat, when to treat and how to treat. The echocardiography is the
investigation of choice to diagnose PDA, estimating the magnitude of shunt volume
and assessing its hemodynamic significance, and to exclude/diagnose any associated
congenital heart defect before any intervention. Various echocardiographic parameters
and staging/scoring systems have been described to help the clincians making the
clinical decisions and some of theses scoring systems are quite complex to apply in
a busy day to day clinical practice. This concised review paper is focused to help
the clinicians in making a clinical decision based upon clincial and echocardiography
parameters. Hence, only the parameters which are commonly used and helpful in making
the clinical decisions in day to day clincial practice have been described in this paper.
Keywords: patent ductus arteriosus (PDA), extreme preterm infants, clinical decision making, echocardiographic
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INTRODUCTION
Patent ductus arteriosus (PDA) is an essential component of the fetal circulation and in most
of the term infants it closes soon after birth. However, PDA is known to remain persistent in
large proportion of extremely low gestational age newborn (ELGAN) infants and its prevalence
is inversely proportional to the gestational age (1). The incidence of a persistent PDA in infants
born <1,000 g or those under 28 weeks of gestation is around 66% (1, 2).
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The important risk factors for persistent PDA include
lower gestational age, lack of antenatal steroids, and need for
mechanical ventilation. The risk of persistent PDA increases with
decreasing gestational age (GA) and lower birth weight (3)1 (4).
Closure is also less likely to occur in infants who have neonatal
respiratory distress syndrome needing mechanical ventilation
and in those who did not receive antenatal corticosteroids (4, 5).
The presence of a persistent PDA is associated with
increased mortality and several significant morbidities including
intraventricular hemorrhage (IVH), pulmonary hemorrhage,
necrotizing enterocolitis (NEC), and chronic lung disease (CLD)
or bronchopulmonary dysplasia (BPD) (6–8). Despite large
number of trials, research studies and scientific efforts in making
an evidence based consensus on how best to manage the
PDA in this vulnerable group of patients, there has been no
agreement on how best to treat or even how best to assess
the PDA and its impact (9). There continues to be a clinical
dilemma who should we treat, how to treat and what the
best strategy in the ELGAN infants is. Different treatment
strategies have been studied over the years. These include
prophylactic treatment, early targeted treatment, treatment of a
clinically symptomatic PDA, the conservative approach of “wait
and watchful policy,” surgical ligation and recently described
percutaneous transcatheter closure of PDA (9–12).
This review focuses at clinical decision making in managing
PDA in the ELGAN infants. The aim of the paper is not to advice
on the type of treatment, but primarily looking on the role of
echocardiography in hemodynamic evaluation of PDAwhich can
help in making clinical decision on the bedside.
CLINICAL DIAGNOSIS OF PDA
The clinical signs of PDA depend upon amount of the shunt
volume passing across the ductus arteriosus; which primarily
depends upon the systemic and pulmonary vascular resistance,
ability of the myocardium to adapt to increased shunt volume
and size of the ductus arteriosus (13–15) (Figure 1).
Infants with even a large PDA often have no clinical signs
in the first few days after birth because of persistently high
pulmonary vascular resistance (PVR) leading to decreased
amount of PDA shunt volume. As PVR drops, shunt volume
increases and infant develops the signs and symptoms of PDA.
Initially, heart murmur may be heard and often the infant is
noted to have fleeting desaturations. As PDA persists then further
signs such as hyperactive precordium, bounding pulses and
widened pulse pressure are recognized and when myocardium
fails to adapt to this increased shunt volume the signs of heart
failure develop (15, 16). However, a small proprotion of ELGAN
infants with decreased myocardial adaptability may develop
hypotension and acidosis even during first few days (16).
Clinical factors and biomarkers can be used both to
diagnose PDA and assess its hemodynamic significance In
hemodynamically significant PDA (hsPDA), signs and symptoms
1Available online at: https://www.uptodate.com/contents/patent-ductus-
arteriosus-in-preterm-infants-pathophysiology-clinical-manifestations-and-
diagnosis/abstract/55.
of pulmonary overcirculation and systemic hypoperfusion are
rated by looking at the oxygenation difficulty, number and
severity of apnea and desaturations, need and extent of non-
invasive or invasive respiratory support, feeding intolerance,
radiologic evidence of cardiomegaly and pulmonary edema,
presence of oliguria, low mean or diastolic hypotension
with or without metabolic acidosis requiring cardiotropic or
vassopressor drugs (17). However, most clinical signs have
limited sensitivity in the first day of life and hence, there is
a few days lag in clinical diagnosis of PDA as compared to
echocardiography (15, 17).
Moreover, it is very difficult to diagnose or rule out underlying
congenital heart defect on clincial examination alone (18).
Hence, echocardiographic diagnosis is mandatory before any
clincial intervention.
ECHOCARDIOGRAPHIC EVALUATION OF
PDA: DIAGNOSIS AND ASSESSMENT OF
HEMODYNAMIC IMPACT OF SHUNT
VOLUME
The echocardiography is the gold standard bedside investigation
to diagnose PDA. In addition to make a confirmative diagnosis of
PDA and exclude/diagnose any associated congenital heart defect
(CHD), it can help in estimating the magnitude of shunt volume
and assessing its hemodynamic significance—it can be used to
assess the hemodynamic impact from pulmonary overcirculation
and systemic hypoperfusion due to shunt volume (13–15).
This could be systematically achieved by studying: (a) ductal
characteristics, (b) parameters of pulmonary overcirculation, and
(c) signs of systemic hypoperfusion (Figure 2).
Various echocardiographic parameters have been described in
the research setting and complex staging/scoring systems (17,
19). This review paper is focused to help the clinicians in making
a clinical decision on the bedside and hence the parameters which
are commonly used and helpful in day to day common clinical
practice have been described.
Echocardiographic Assessment of Ductal
Characteristics
The echocardiography can be used to assess the size of PDA
by measuring transductal diameter, interrogate shunt direction,
and velocity of blood flow across the ductus arteriosus can be
measured by using Doppler technique.
Measuring Transductal Diameter
Although the PDA can be visualized from many windows,
the high left-sided parasternal “ductal” view is the preferred
window to obtain a clear 2D image and accurately measure
size of the ductus arteriosus. PDA size is measured from
the transductal diameter at the site of maximum constriction
(narrowest dimension), which is usually at the pulmonary end
(20).Most studies have describedmeasuring PDA size using color
Doppler, although with new ultrasound machines and through
proper training it can be easily measured on 2D image. If color
Doppler is used to measure the duct size the gain setting should
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FIGURE 1 | Diagram showing impact of significant left to right shunt across ductal arteriosus (DA) leading to pulmonary over-circulation and systemic hypoperfusion.
Spectrum of clinical features in preterm infants depends upon magnitude of ductal shunt, which depends upon DA size and balance between systemic and
pulmonary vascular resistance, and inability of immature myocardium to adpat to circulatory disturbance. PDA, patent ductus arteriosus; SVR, systemic vascular
resistance; PVR, pulmonary vascular resistance.
FIGURE 2 | Summary of an approach to echocardiographic assessment of PDA and hemodynamic evaluation; LA, left atrium; LV, left ventricle; DA, ductus arteriosus;
Ao, aorta; SMA, superior mesenteric artery; ACA, anterior cerebral artery; MCA, middle cerebral artery; SVC, superior vena cava.
be adequately optimized to minimize the risk of over-estimation.
Color compare or simultaneous mode, which allows putting 2D
and color Doppler image side by side, can be applied to measure
ductal size in both modes using frame by frame technique
(Figure 3).
Direction of Shunt Across Ductus Arteriosus
The direction of the ductal shunt depends upon the relationship
between the pulmonary and systemic pressures. It is assessed
using color Doppler and direction of blood flow across ductus
arteriosus is normally left to right, from the aorta (high systemic
pressure) to the pulmonary artery (low pulmonary pressure)
but it can be right to left or bi-directional when there is high
pulmonary vascular resistance or when there is anatomical cause
(due to certain CHDs). With conventional setting left to right
shunt is seen as red jet while right to left shunt is seen as
blue (21). A right-to-left shunt across the PDA is more difficult
to see because color Doppler will show it as a blue jet, blood
going toward aorta from pulmonary end, similar to branch
pulmonary arteries. Color compare or simultaneous mode can
be very helpful in such situation. Bi-directional flow is often
seen during transitional circulation or when the pulmonary
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FIGURE 3 | Measurement of ductal size on 2D and color Doppler on high left parasternal “ductal view.” (A) Showing significant discrepency between ductal diameter
measurement on 2D and color Doppler—over-estimation of ductal size on color Doppler because of gain setting; (B) showing no significant discrepency between
ductal diameter measurement on 2D and color Dopple after optimisation of gain setting. LPA, left pulmonary artery; RPA, right pulmonary artery; PDA, patent ductus
arteriosus.
FIGURE 4 | Assessment of PDA shunt direction on color flow and with Doppler application. (A) Left to right shunt seen as red (blood coming toward probe) while
blood in branch pulmonary arteries seen as blue (blood going away from probe); (B) showing right to left shunt seen as blue color—similar to branch pulmonary
arteries in a view “three legged trouser;” (C) Doppler assessment showing left to right shunt (above the baseline as blood coming toward the probe); and (D) Doppler
assessment showing right to left shunt (below the baseline as blood going away from the probe). LPA, left pulmonary artery; RPA, right pulmonary artery; PDA, patent
ductus arteriosus.
artery pressures are equal to systemic pressures (21). Shunt
direction can also be assessed using pulse or continuous wave
Doppler where left to right shunt is seen above the baseline
(blood coming toward the probe) while right to left shunt is
seen below the baseline (blood going away from the probe)
(15, 21) (Figure 4).
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FIGURE 5 | Assessment of restrictive and non-restrictive (pulsatile) flow pattern on Doppler assessment of PDA. (A) Showing non-restrictive (pulsatile) flow pattern
with end-diastolic velocity (EDV) less than half of the peak systolic velocity; and (B) showing restrictive flow pattern with end-diastolic velocity (EDV) more than half of
the peak systolic velocity.
FIGURE 6 | Assessment of left heart volume overloading on visual inspection “eyeballing.” (A) Apical 4 chamber view in 2D showing dilated left side of the heart
(dilated left atrium and left ventricle); (B) Mitral regurgitation on color flow mapping as blue jet going back to left atrium (see explanation in text); (C) “Crab view”
showing dilated pulmonary veins reflecting increased pulmonary venous return and (D) Dilated left atrium in parasternal short axis view—on visual inspection LA looks
almost the double the size of aortic valve (Ao). LA, left atrium; LV, left ventricle; RA, right atrium; RV, right ventricle; Ao, aortic valve; RUPV, right upper pulmonary vein;
RLPV, right lower pulmonary vein; LLPV, left lower upper pulmonary vein.
Velocity of Shunt Across PDA and Its Significance
The shunt velocity across the PDA during the cardiac cycle
can be obtained by applying pulse or continuous wave Doppler
in the ductus arteriosus. The maximum velocity during systole
and diastole can be measured. Non-restrictive shunts have a
low peak systolic velocity with a high systolic to end-diastolic
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FIGURE 7 | Assessment of left atrium (LA) to aorta (Ao) ratio in parasternal
long axis view. LA and Ao diameter measurement shown using M-mode and
cartoon schematic diagram.
velocity gradient while restrictive shunts have a high peak systolic
velocity and a low systolic to diastolic velocity gradient. If the
ratio between peak systolic and end-diastolic velocity is >2 then
it is considered as a pulsatile flow pattern while a ratio of <2 is




The increased pulmonary blood flow from a significant left-to-
right ductal shunt leads to pulmonary blood flow and hence
increased pulmonary venous return. This leads to increased
volume overload in the left atrium (LA) which gradually gets
dilated and if this process of significant left to right shunt persists
then it leads to dilatation of left ventricle from increased preload,
especially in absence of a large intra-atrial shunt. As aortic valve
annulus (Ao) is a relatively fixed structure and it does not get
dilated due to left heart overloading. Hence, a ratio of LA/Ao
can be used as a surrogate of increased pulmonary venous return
(24, 25). Similarly, the left ventricular end diastolic diameter
(LVEDD) can be used as surrogate markers for pulmonary
venous return. In clinical practice the volume overloading of
the left heart can be subjectively assessed by “eyeballing” (15)
(Figure 6).
Both LA/Ao ratio and LVEDD can be measured from the
parasternal long axis view using M-mode with the cursor
perpendicular to the aorta at the level of the aortic valve or at
the septum at the tip of the mitral valve leaflets, respectively
(Figure 7). LA/Ao ratio of >1.4 is considered significant and
has been used as a cut-off value in many clinical trials (25).
The normal reference ranges for LVEDD in preterm infants in
relation to body weight and postnatal age have been published
and z-scores should be used for LVEDD (26).
Variable degree of mitral valve insufficiency is often seen
in infants with persistent large PDA and significant left heart
FIGURE 8 | Doppler assessment of blood flow in left pulmonary artery (LPA)
showing increased diastolic velocity indicative of significant ductal shunt in
diastole leading to turbulence and increased velocity.
dilatation (Figure 6). It occurs due to left atrial dilatation
resulting in stretching of mitral valve and left ventricular volume-
overloading. The mitral valve regurgitation usually improves
significantly with normalization of left atrial size and resolves
completely within weeks after PDA closure (14, 26, 27).
While assessing left heart volume overloading one should be
mindful of intra-atrial shunt. A large left-to-right shunt through
the foramen ovale or septal defect can “offload” the left side of the
heart even in the presence of a significant ductal shunt leading to
an artificially low/normal LA/Ao ratio or low LVEDD.
The presence of forward pulmonary flow in diastole in the left
pulmonary artery (LPA) has been described as a sign of significant
left to right shunt through the PDA. Using pulsed wave Doppler
in the LPA mean and end-diastolic velocity can be measured
and cut-off points of 0.42 and 0.20 m/s, respectively, have been
described as indicative of significant ductal shunt (24) (Figure 8).
The mitral valve E/A ratio refers to the ratio of the velocity
of the early (E) diastolic phase of ventricular filling vs. the
late atrial (A) contraction component. Mitral valve E/A ratio
can be obtained from apical 4-chamber view with the pulsed
Doppler range gate set slightly below the mitral valve annulus. In
preterm infants, mitral valve E/A ratio is usually <1 due to poor
compliance of the myocardium leading to moderate impairment
of diastolic performance and low early diastolic filling velocity.
In the presence of a hsPDA, atrial pressure increases because
high pulmonary venous return and this leads to a reversal of
the E/A ratio >1. Various other echocardiographic parameters
have been studied and described to assess pulmonary circulation
such as left ventricular output (LVO) to superior vena cava
flow (SVC) ratio, and decreased isovolumic relaxation time
(IVRT) using tissue Doppler Imaging (TDI) (13, 24, 28). There
may be limited expertise in doing TDI assessment accurately
on neonatologist performed echocardiography. On the other
hand, echocardiographic assessments (such as SVC flow and
LVO estimation) needing multiple parameters are not only time
consuming but also has potential to make errors in measurement
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FIGURE 9 | Doppler assessment of blood flow in descending aorta (post-ductal flow). (A) Showing forward blood flow during disatole; and (B) showing retrograde
blood flow during diastole indicating “ductal steal” in presence of a large PDA.
FIGURE 10 | Color flow mapping and Doppler assessment of blood flow in the coeliac trunk and superior mesenteric artery in sub-costal sagittal view. (A) Showing
color flow mapping of the coeliac and superior mesenteric arteries; and (B) showing retrograde blood flow during diastole in the the coeliac and superior mesenteric
arteries indicating “ductal steal” in presence of a large PDA.
and significant intra- and inter-observer variability (29–32).
Hence, the common echocardiographic parameters often used
in clinical decision making on the bedside remain qualitative
assessment on visual inspection “eyeballing,” LA/Ao ratio and
LVEDD measurement. Mitral E/A ratio is easy to measure but
one should be mindful that even in preterm infants with no
hsPDA E/A ratio gradually become >1 with time as myocardium
compliance improves.
Echocardiographic Evaluation of Systemic
Hypoperfusion
In the presence of a large PDA, blood shunts away from the
systemic circulation throughout the cardiac cycle, however, this
becomes more apparent during diastole and it can be studied
using Doppler on echocardiography (15, 31). Retrograde or
absent blood flow during diastole in descending aorta below
the ductal ampulla or in the coeliac axis or superior mesenteric
artery have been described as indicator of significant PDA shunt
leading to systemic steal (systemic hypoperfusion) (24, 32).
Doppler flow patterns from the descending aorta can be obtained
from a suprasternal or high parasternal view with the pulsed
wave Doppler sample gate placed distal to the origin of ductus
arteriosus (ductal ampulla) (Figure 9).
Similarly, celiac trunk or superior mesenteric artery can
be interrogated using pulsed wave Doppler in the sagittal
abdominal view (Figure 10). Doppler assessment of the anterior
cerebral artery in the mid-sagittal view of brain ultrasound
can be performed and retrograde flow during diastole would
suggest significant ductal shunt—similar to coeliac or superior
mesentery artery Doppler assessment. However, to date the
clinical relevance and long term outcomes of the deranged
cerebral Doppler flow patterns remain unknown (33).
Based upon the clinical and echocardiographic criteria various
staging systems been described and have been shown to help
in decision making for intervention (17, 19). However, in
authors experience they have not been widely adopted in
the clinical practice which could be possibly because of their
extensive number of parameters. Recently, van Laere et al.
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TABLE 1 | Summary of essential parameters used for echocardiographic
assessment and hemodynamic evaluation of PDA in ELGAN infants.
PDA evaluation
criteria
Essential echocardiographic parameters for




• PDA size (small <1.5mm, moderate 1.51–2mm,
large >2mm) and flow direction (left to right, right to
left, or bi-directional) and Doppler assessment with





• Dilated left side of the heart on visual inspection
“eyeballing” and LA/Ao ratio (mild <1.4, moderate
1.41–1.6, severe >1.6) OR LVEDD (correlate with
z-scores) OR LPA diastolic velocity, mean velocity
>0.42 m/s, end-diastolic velocity >0.2 m/s OR
Reversal of mitral E/A ratio *Document presence or




• Retrograde or absent blood flow during diastole in:
-descending aorta OR
-coeliac trunk or superior mesenteric artery (SMA)
OR
-anterior or middle cerebral artery
A comprehensive echocardiographic assessment should be performed to rule out any
underlying congenital heart defect or pulmonary hypertension and delineate orientation of
arch (left or right sidedness) before any intervention to close the PDA.
(13) suggested essential various echocardiographic parameters
including measuring left ventricular output in all infants needing
assessment of PDA. However, in authors experience these
staging systems needing extensive echocardiographic parameters
assessment have not been widely adopted in the clinical
practice. We have summarized the commonly used parameters
which would help the clinicians assessing the PDA and its
hemodynamic significance on echocardiography, and in making
clinical decisions in the clinical practice.
CLINICAL DECISION MAKING: IS THE PDA
HEMODYNAMICALLY SIGNIFICANT?
The above echocardiographic parameters summarized in Table 1
may help in addressing the issue of whether the PDA is
hemodynamically significant or not. However, the definition
of an hsPDA continues to evolve. In addition to multiple
echocardiographic indices described above, the hemodynamic
significance of a persistent PDA should be interpreted by
considering the gestational and chronological age, and by
assessing the vulnerability of organs at risk for overflow (the
lungs), or hypoperfusion (e.g., the brain, intestines, and kidneys).
Further work is needed to reach a consensus on how to define
and manage a hemodynamically significant persistent PDA in
extremely preterm infants (34).
A large PDA with some or all the signs of hemodynamic
significance can be seen in a well infant needing no or minimal
ventilatory support, and it may not be clinically significant. There
is high rate of spontaneous closure of PDA, even in ELGAN
infants, if they are left alone (35, 36). On the other hand, a PDA
with similar parameters on echocardiography may be associated
with significant hemodynamic instability and co-morbidities
(5, 6). The debate remains whether well asymptomatic infants
with echocardiographic parameters suggestive of large or
hemodynamically significant should be treated or not (37–40).
In the last few years, there has been move toward conservative
“watchful” approach in infants with no significant clinical signs
even when there are echocardiographic parameters suggestive
of large hsPDA (9). The published evidence does not support
treating an infant with an echocardiographic parameters
suggestive of hsPDA without any significant clinical signs of
PDA. Large trials have failed to demonstrate any long term
benefit (such as death or BPD) from PDA treatment, although
they demonstrated short term benefits in terms of decreasing
incidence of large intraventricular hemorrhage or pulmonary
hemorrhage (39). However, these trials were underpowered to
study the long term effects and even more importantly most of
these trials used very limited echocardiography dataset to enroll
infants (39–43). Hence, in the absence of evidence the debate
of whether to treat or not continues and in fact when to treat,
how to treat and who to treat remains controversial. There is
no consensus on management of PDA in the extremely preterm
infants and even there is no consensus on the definition of the
commonly used term “hsPDA.”
Most clinicians would agree that ductus arteriosus with
echocardiographic parameters suggestive of large PDA associated
with pulmonary over-circulation and systemic hypoperfusion
should be regarded as hsPDA (44). Infants with clinical signs
of heart failure and echocardiographic signs of a hsPDA
would benefit from treatment. They should be treated with
diuretic therapy to offload the heart (decrease preload) and
they may benefit from fluid restriction, especially if they are
on fluid therapy. This approach would help in cardiovascular
stabilization prior to definitive intervention (medical, surgical, or
transcatheter approach). Whether all hsPDA should be treated
or not, and if treated how best they should be treated, remains
debatable. In authors’ opinion, infants with echocardiographic
signs of hsPDA should be either treated or carefully monitored
with low threshold for intervention if clinical condition worsens
or does not improve.
The treatment intervention varies from no intervention
(“wait and watchful” policy) to treating all PDAs diagnosed
on echocardiography. “One size may not fit all”—this truly
applies on managing PDA in ELGAN infants with huge variation
in clinical course and associated co-morbidities. The lack of
evidence on how to best evaluate the PDA in these infants
probably results in lack of consensus among the scientific
bodies, or even among the clinicians within the same unit (45).
The intervention options are: no intervention (conservative
management), pharmacological treatment (prophylactic
medication, early targeted intervention and treatment of
symptomatic infants), transcatheter closure and surgical ligation
of PDA.
Studies of prophylactic treatments using indomethacin
show reduced rates acute pulmonary hemorrhage, intracranial
hemorrhage, and surgical ligation (39). It does however expose
large proportion of infants to indomethacin who do not
need treatment because of spontaneous closure. Studies on
prophylactic use of ibuprofen failed to show the benefits reported
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FIGURE 11 | A simple algorithm to clinical decision making in extremely low gestational age newborn infants (ELGAN). Clinical decision whether to treat or follow up
should be made based upon both clinical and echocardiography assessment. NEC, necrotizing enterocolitis; IVH, intraventricular hemorrhage; ELGAN, extremely low
gestational age newborn infants; hsPDA, hemodynamically significant patent ductus arteriosus.
on using indomethacin (46).Many ongoing studies (BabyOSCAR
trial, French TRIOCAPI trial, Dutch BeNEDuCTUS trial, and
Australian U-PDA trial focused on the short term and long term
outcomes of early targeted treatment approaches2.
With advances in technologies and expertise, PDA can be
closed via transcatheter route with faster recovery and avoiding
the risk of complications from surgery. This can now be safely
done in ELGAN infants weighing over 700 g (47, 48). A detailed
discussion about the evidence for various treatment options is
beyond the scope of this review article.
The authors recommend a comprehensive assessment of PDA
and its hemodynamic significance before making any clinical
decision to treat or not and the clinical decision making should
be made in clinical context of the individual infant. A simple
algorithm to clinical decision making based upon clinical and
echocardiographic assessment, whether to treat or follow up, has
been summarized in Figure 11. Moreover, this can be dynamic
decision, especially in infants with conservative management and
serial assessment on neonatologist performed echocardiography
can help in making timely individualized decision making.
CONCLUSION
While the best treatment option to treat the PDA in the extremely
low gestational age newborn infants remains debatable and lacks
2Available online at: https://clinicaltrials.gov/ct2/results?term=pDA&Search=
Apply&recrs=a&age.
consensus at this stage, there has been significant progress in
assessing hemodynamic significance of the ductal shunt. Before
making a clinical decision to treat a PDA or not, all infants
should have a comprehensive structural assessment to rule out
any underlying CHD and a meticulous hemodynamic evaluation
to assess the impact of PDA shunt on the pulmonary over-
circulation and systemic hypoperfusion. In absence of clear
evidence, the clinical decision should be individualized based
upon clinical concerns and echocardiographic assessment. While
in some infants a careful “wait and watchful” strategy may be
the best option, other infants may need early intervention to
minimize the co-morbidities. There is an urgent need of studying
the long term outcomes in the sub-set of infants with hsPDA
identified on meticulous echocardiographic assessment.
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